# Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus

> **NCT05102149** · PHASE3 · UNKNOWN · sponsor: **PegBio Co., Ltd.** · enrollment: 672 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus (T2DM)

## Interventions

- **DRUG:** PB-201
- **DRUG:** Vildagliptin
- **DRUG:** PB-201 matched placebo
- **DRUG:** Vildagliptin matched placebo

## Key facts

- **NCT ID:** NCT05102149
- **Lead sponsor:** PegBio Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-30
- **Primary completion:** 2023-11
- **Final completion:** 2025-04
- **Target enrollment:** 672 (ESTIMATED)
- **Last updated:** 2022-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05102149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05102149, "Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05102149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*